![](/img/cover-not-exists.png)
[BMJ Publishing Group Ltd IGCS Annual 2019 Meeting Abstracts - ()] E-Poster viewings - 312â Aries: a phase 2, open-label study to evaluate rucaparib (PARP inhibitor) in combination with nivolumab (Anti-PD-1 Antibody) in patients with ovarian or urothelial cancer (UC)
Moore, K, Redhead, K, Goble, S, Bowles, O, Lin, KK, Tripathi, ADOI:
10.1136/ijgc-2019-igcs.312
File:
PDF, 73 KB